Clinical application of combination [11C]C-methionine and [13N]N-ammonia PET/CT in recurrent functional pituitary adenomas with negative MRI or [18F]F-FDG PET/CT
Tóm tắt
We assessed the value of positron emission tomography/computed tomography (PET/CT) with [13N]N-ammonia ([13N]N-NH3) and [11C]C-methionine ([11C]C-MET) for the evaluation and management of recurrent secreting pituitary adenoma, which could not be detected by magnetic resonance imaging (MRI) or fluorine-18 fluorodeoxyglucose ([18F]F-FDG) PET. Nine consecutive patients with biochemical and clinical evidence of active recurrent tumor not detected by MRI and [18F]F-FDG PET were enrolled in this study. All of the patients underwent [13N]N-NH3 and [11C]C-MET PET/CT, after which the pattern of tracer uptake was studied, the tumor position was located, and a clinical decision was made. In general, [11C]C-MET had a higher uptake in pituitary adenomas (PAs) than that in pituitary tissues, while [13N]N-NH3 had a higher uptake in pituitary tissue than in pituitary adenomas. Increased [11C]C-MET uptake was observed in all nine PAs and three pituitary tissues, while all pituitary tissues and only one pituitary adenoma showed increased [13N]N-NH3 uptake. Four patients had concordant imaging and surgical findings indicative of biochemical remission without hypopituitarism after treatment. Radiotherapy was adopted in two patients, medication in another two, and follow-up observation in one case. Combined [11C]C-MET and [13N]N-NH3 PET/CT is effective in the differentiation of PAs from pituitary tissue in recurrent functional PAs with negative MRI or [18F]F-FDG PET. These results provide a valuable reference for further disease management.
Tài liệu tham khảo
Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, et al. The prevalence of pituitary adenomas: a systematic review. Cancer. 2004;101:613–9.
Molitch ME. Diagnosis and Treatment of Pituitary Adenomas: A Review. JAMA. 2017;317:516–24.
Roelfsema F, Biermasz NR, Pereira AM. Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary. 2012;15:71–83.
Slagboom TNA, Stenvers DJ, van de Giessen E, Roosendaal SDD, de Win MML, Bot JCJ, et al. Continuing Challenges in the Definitive Diagnosis of Cushing’s Disease: A Structured Review Focusing on Molecular Imaging and a Proposal for Diagnostic Work-Up. J Clin Med. 2023;12:2919.
Bergström M, Muhr C, Lundberg PO, Långström B. PET as a tool in the clinical evaluation of pituitary adenomas. J Nucl Med. 1991;32:610–5.
Tang BNT, Levivier M, Heureux M, Wikler D, Massager N, Devriendt D, et al. 11C-methionine PET for the diagnosis and management of recurrent pituitary adenomas. Eur J Nucl Med Mol Imaging. 2006;33:169–78.
Feng Z, He D, Mao Z, Wang Z, Zhu Y, Zhang X, et al. Utility of 11C-Methionine and [18F]F-FDG PET/CT in Patients With Functioning Pituitary Adenomas. Clin Nucl Med. 2016;41:e130-134.
Tomura N, Saginoya T, Mizuno Y, Goto H. Accumulation of 11C-methionine in the normal pituitary gland on 11C-methionine PET. Acta Radiol. 2017;58:362–6.
Xiangsong Z, Dianchao Y, Anwu T. Dynamic 13N-ammonia PET: a new imaging method to diagnose hypopituitarism. J Nucl Med. 2005;46:44–7.
Zhang F, He Q, Luo G, Long Y, Li R, Ding L, et al. The combination of 13N-ammonia and 11C-methionine in differentiation of residual/recurrent pituitary adenoma from the pituitary gland remnant after trans-sphenoidal Adenomectomy. BMC Cancer. 2021;21:837.
Wang Z, Mao Z, Zhang X, He D, Wang X, Du Q, et al. Utility of 13N-Ammonia PET/CT to Detect Pituitary Tissue in Patients with Pituitary Adenomas. Acad Radiol. 2019;26:1222–8.
d’Amico A, Stąpór-Fudzińska M, Tarnawski R. CyberKnife radiosurgery planning of a secreting pituitary adenoma performed with 68Ga DOTATATE PET and MRI. Clin Nucl Med. 2014;39:1043–4.
Hyun SH, Choi JY, Lee K-H, Choe YS, Kim B-T. Incidental focal [18F]F-FDG uptake in the pituitary gland: clinical significance and differential diagnostic criteria. J Nucl Med. 2011;52:547–50.
Ikeda H, Abe T, Watanabe K. Usefulness of composite methionine-positron emission tomography/3.0-tesla magnetic resonance imaging to detect the localization and extent of early-stage Cushing adenoma. J Neurosurg. 2010;112:750–5.
Farhat H, Ciric I. The utility of metabolic testing in the diagnosis of residual and recurrent acromegaly. World Neurosurg. 2014;82:327–8.
Rodriguez-Barcelo S, Gutierrez-Cardo A, Dominguez-Paez M, Medina-Imbroda J, Romero-Moreno L, Arraez-Sanchez M. Clinical usefulness of coregistered 11C-methionine positron emission tomography/3-T magnetic resonance imaging at the follow-up of acromegaly. World Neurosurg. 2014;82:468–73.
Wang H, Hou B, Lu L, Feng M, Zang J, Yao S, et al. PET/MRI in the Diagnosis of Hormone-Producing Pituitary Microadenoma: A Prospective Pilot Study. J Nucl Med. 2018;59:523–8.
Zhao X, Xiao J, Xing B, Wang R, Zhu Z, Li F. Comparison of (68)Ga DOTATATE to [18F]F-FDG uptake is useful in the differentiation of residual or recurrent pituitary adenoma from the remaining pituitary tissue after transsphenoidal adenomectomy. Clin Nucl Med. 2014;39:605–8.
Ding D, Starke RM, Sheehan JP. Treatment paradigms for pituitary adenomas: defining the roles of radiosurgery and radiation therapy. J Neurooncol. 2014;117:445–57.